Neurocrine Biosciences (NBIX) Shares Outstanding (2010 - 2026)

Neurocrine Biosciences has reported Shares Outstanding for 17 years, with the latest figure at $100.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 1.62% year-over-year to $100.6 million; the trailing twelve-month figure through Mar 2026 stood at $100.6 million (up 1.62% YoY), and the FY2025 full-year result was $100.1 million, up 0.7% from the prior year.
• Shares Outstanding for Q1 2026 stood at $100.6 million, roughly flat from $100.1 million in the prior quarter.
• The five-year high for Shares Outstanding was $101.2 million in Q3 2024, with the low at $95.5 million in Q1 2022.
• Historically, Shares Outstanding has averaged $98.6 million across 5 years, with a median of $99.0 million in 2025.
• Annual changes were most pronounced in 2024 — Shares Outstanding increased 3.38% — and 2025, when it dropped 1.88%.
• Neurocrine Biosciences' Shares Outstanding stood at $96.5 million in 2022, then advanced by 2.28% to $98.7 million in 2023, then rose by 0.71% to $99.4 million in 2024, then advanced by 0.7% to $100.1 million in 2025, then gained by 0.5% to $100.6 million in 2026.
• The last three Shares Outstanding figures came in at $100.6 million (Q1 2026), $100.1 million (Q4 2025), and $99.7 million (Q3 2025), per Business Quant data.